Author

James S. Rush

Observed names: J Rush, J S Rush, J. Rush, J. S. Rush, J.S. Rush, JS Rush, James Rush, James S Rush, James S. Rush, Rush, J., Rush, James, Rush, James A., Rush, James S

Observed institutions: Genomics Institute of the Novartis Research Foundation, Novartis (Switzerland), The University of Sydney, Howard Hughes Medical Institute, Centenary Institute, Yale University, Novartis Institutes for BioMedical Research, Novartis Foundation

ORCID: 0000-0001-5846-448X

Observed ORCID: 0000-0001-5846-448X

OpenAlex ID: A5066726905

Targeting co-stimulatory molecules in autoimmune disease

2020 · Natalie M. Edner, Gianluca Carlesso, et al. · Nature Reviews Drug Discovery · 229

TNF leads to mtDNA release and cGAS/STING-dependent interferon responses that support inflammatory arthritis

2021 · Joschka Willemsen, Marie-Therese Neuhoff, et al. · Cell Reports · 227

PDF

Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers

2021 · C. Glenn Begley, Mark Ashton, et al. · Science Translational Medicine · 154

Quantitative analysis of lymphocyte differentiation and proliferation in vitro using carboxyfluorescein diacetate succinimidyl ester

1999 · J Hasbold, AV Gett, et al. · Immunology and Cell Biology · 133

Deficiency of MALT1 Paracaspase Activity Results in Unbalanced Regulatory and Effector T and B Cell Responses Leading to Multiorgan Inflammation

2015 · Frédéric Bornancin, Florian Renner, et al. · The Journal of Immunology · 131

PDF

Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study

2020 · Benjamin A Fisher, Antonia Szanto, et al. · The Lancet Rheumatology · 129

Staggered AID-dependent DNA double strand breaks are the predominant DNA lesions targeted to S in Ig class switch recombination

2004 · J. S. Rush · International Immunology · 102

A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, for Control of Graves Hyperthyroidism—A Proof-of-Concept Trial

2019 · George J Kahaly, Marius Nicolae Stan, et al. · The Journal of Clinical Endocrinology & Metabolism · 99

B cells activated via CD40 and IL-4 undergo a division burst but require continued stimulation to maintain division, survival and differentiation

2001 · James S. Rush, Philip D. Hodgkin · European Journal of Immunology · 98

PDF

Expression of activation-induced cytidine deaminase is regulated by cell division, providing a mechanistic basis for division-linked class switch recombination

2005 · James S. Rush, Man Liu, et al. · Proceedings of the National Academy of Sciences · 97

First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody

2019 · Pascal Espié, YanLing He, et al. · American Journal of Transplantation · 92

Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody

2018 · Jacinda Ristov, Pascal Espie, et al. · American Journal of Transplantation · 90

A Novel, Blocking, Fc-Silent Anti-CD40 Monoclonal Antibody Prolongs Nonhuman Primate Renal Allograft Survival in the Absence of B Cell Depletion

2015 · F. Cordoba, G. Wieczorek, et al. · American Journal of Transplantation · 81

PDF

Single-cell transcriptomic analysis of renal allograft rejection reveals insights into intragraft TCR clonality

2023 · Tiffany Shi, Ashley R. Burg, et al. · Journal of Clinical Investigation · 52

PDF

Preclinical characterization of the Toll-like receptor 7/8 antagonist MHV370 for lupus therapy

2023 · Stuart Hawtin, Cédric André, et al. · Cell Reports Medicine · 43

PDF

Blockade of CD40–CD154 pathway interactions suppresses ectopic lymphoid structures and inhibits pathology in the NOD/ShiLtJ mouse model of Sjögren's syndrome

2019 · Grazyna Wieczorek, Marc Bigaud, et al. · Annals of the Rheumatic Diseases · 40

Cross-Linking Surface Ig Delays CD40 Ligand- and IL-4-Induced B Cell Ig Class Switching and Reveals Evidence for Independent Regulation of B Cell Proliferation and Differentiation

2002 · James S Rush, Jhagvaral Hasbold, et al. · The Journal of Immunology · 40

A new TLR2 agonist promotes cross-presentation by mouse and human antigen presenting cells

2015 · Melissa Santone, Susanna Aprea, et al. · Human Vaccines & Immunotherapeutics · 30

PDF

Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study

2023 · Baltazar GomezMancilla, Matthew N. Meriggioli, et al. · Journal of Clinical Neuroscience · 28

Biologic Treatment in Combination with Lifestyle Intervention in Moderate to Severe Plaque Psoriasis and Concomitant Metabolic Syndrome: Rationale and Methodology of the METABOLyx Randomized Controlled Clinical Trial

2021 · Andreas Pinter, Peter Schwarz, et al. · Nutrients · 28

PDF

AB0155 Learning sle pathological mechanisms from multi 'omics profiles

2017 · SS Pfister, N Kelley, et al. · Annals of the Rheumatic Diseases · 19

PDF

Non‐redundancy of cytidine deaminases in class switch recombination

2004 · Sebastian D. Fugmann, James S. Rush, et al. · European Journal of Immunology · 19

The logic of intercellular communication in the immune system

1998 · PD Hodgkin, J Rush, et al. · Immunology and Cell Biology · 19

Nonclinical Safety Assessment of CFZ533, a Fc-Silent Anti-CD40 Antibody, in Cynomolgus Monkeys

2018 · Peter Ulrich, Thierry Flandre, et al. · Toxicological Sciences · 18

Novel Anti-CD40 Monoclonal Antibody CFZ533 in Patients with Primary Sjogren Syndrome: A Phase Iia Double-Blind, Placebo–Controlled Randomized Trial

2018 · Arwa Farag, Athena Papas, et al. · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · 14

Works count: 53

Citation count: 2,070

H-index: 20

I10-index: 27